Yinlin Jack Chen - Aug 10, 2023 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Role
SVP, Finance
Signature
/s/Lillian Smith, Attorney-in-Fact
Stock symbol
ALLO
Transactions as of
Aug 10, 2023
Transactions value $
$0
Form type
4
Date filed
8/14/2023, 07:59 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALLO Common Stock Award $0 +11.4K +14.71% $0.00 88.9K Aug 10, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALLO Stock Option (Right to Buy) Award $0 +39.2K $0.00 39.2K Aug 10, 2023 Common Stock 39.2K $4.21 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the stock option shall vest on August 10, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter.